Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patientsShumin Yuan, Zibing Wang, Yuqing Liu et al.|Cancer Immunology Immunotherapy|2022Cited by 19